KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Depreciation & Amortization (CF) (2016 - 2025)

Eli Lilly's Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $585.7 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 20.71% year-over-year to $585.7 million; the TTM value through Dec 2025 reached $2.0 billion, up 13.02%, while the annual FY2025 figure was $2.0 billion, 13.02% up from the prior year.
  • Depreciation & Amortization (CF) reached $585.7 million in Q4 2025 per LLY's latest filing, up from $470.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $585.7 million in Q4 2025 to a low of $348.9 million in Q2 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $418.1 million, with a median of $405.8 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): increased 28.03% in 2021, then decreased 16.85% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $445.7 million in 2021, then decreased by 15.86% to $375.0 million in 2022, then grew by 3.31% to $387.4 million in 2023, then rose by 25.25% to $485.2 million in 2024, then grew by 20.71% to $585.7 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's Depreciation & Amortization (CF) are $585.7 million (Q4 2025), $470.0 million (Q3 2025), and $478.5 million (Q2 2025).